- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01280084
Labour Analgesia and Movement in Babies (LAMB)
The Effect of Labour Analgesia on Babies' Movements After Birth: An Actigraphic Study
연구 개요
상태
상세 설명
The purpose of the study is to investigate the potential utility of actigraphy, a non-invasive means of measuring an individual's movements, in distinguishing the effects of different types of maternal labour analgesia on babies after birth.
The study hypothesizes that actigraphic data can be used to differentiate the effects on neonates of different forms of maternal intrapartum analgesia. In particular, we hypothesize that infants of mothers who receive intrapartum opioid analgesia will demonstrate fewer movements than infants of mothers who receive epidural analgesia or those who receive nothing.
Whilst it is well known that drugs administered to mothers during labour can affect their babies, means of assessing this effect are complex and unreliable. A more objective means of assessing babies after birth is required, and actigraphy may represent a useful technique. Actigraphy has been used on babies in other studies in a variety of settings, including comparing babies born by different delivery modes (i.e. vaginal versus cesarean delivery) and at different gestations (i.e. term versus preterm), although none of these studies have considered maternal analgesia received prior to delivery as a possible influence on babies' movements after birth. Other studies that have looked at sleep parameters in babies, particularly measures of activity, have shown association with later indices of psychomotor development.
The objective of the study is to compare actigraph-derived movement data from babies whose mothers have received any of the commonly used analgesic techniques for labour at BC Women's Hospital.
This is a prospective observational study. Women will be assessed for eligibility for the study on admission to the labour ward. As one of the inclusion criteria is vaginal birth, women considered eligible on admission may become ineligible depending on their mode fo delivery. Information will be available to all women in the assessment rooms and consent will be specifically sought after they deliver and are deemed eligible. We plan to recruit the babies of mothers who receive analgesia in one of four categories: no analgesia or nitrous oxide only; systemically administered opioid analgesia only; epidural analgesia with an intermediate total dose of fentanyl (<150mcg); epidural analgesia with a high total dose of fentanyl (>150mcg). We recognize that women may receive several or even all of the different modalities of labour analgesia in the course of their delivery. In this situation, we will calculate the total dose fo opioid received by all routes and convert this to fentanyl equivalents for the purposes of analysis. Neonates of women who agree to participate will be fitted with an actigraph that will remain in place (except for removal for bathing) for 24 hours, or until discharge from hospital. Actigraphs are small, light-weight, wrist-watch-sized monitors that weight 16 grams. The actigraphs will be placed on the neonates' ankle, as this position has been reported to cause less disturbance to them. Parents of participating neonates will also be instructed in the use fo a daily dairy that will allow correlation of actigraphic movement data with events such as bathing (when the actigraph will necessarily be removed) and other external sources of movements (e.g. being rocked, breastfeeding).
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6H 3N1
- British Columbia Women's Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Neonates born to healthy women with singleton pregnancies who deliver vaginally at term gestation (> 37 weeks)
- Mothers aged 19 years or older and understand written and oral English
- Neonates who are neurologically healthy
Exclusion Criteria:
- Cesarean delivery; patients booked for cesarean delivery presenting in labour
- Maternal opioid dependence
- Maternal sedative or psychotropic medications
- Maternal combined spinal epidural (CSE) analgesia in labour
- Forceps delivery; 4th degree perineal tears
- Birth weight greater than 4.5 kg
- Intrapartum fetal heart rate abnormalities requiring immediate delivery
- Neonates of mothers who receive epidural morphine for post-delivery analgesia
- Neonates requiring admission to NICU
- Neonates with obvious congenital anomalies
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
No labour analgesia/nitrous oxide
Women who use no analgesia during labour or who only used nitrous oxide.
|
|
Systemic opioids
Women who receive only systemic opioids for analgesia during, either intravenously or intramuscularly
|
|
Intermediate dose epidural fentanyl
Women who receive a total epidural fentanyl dose less than 150 micrograms
|
|
High dose epidural fentanyl
Women who receive a total epidural fentanyl dose more than 150 micrograms
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Neonates' mobile and immobile time in 24 hours
기간: Within the first 24 hours of life
|
Within the first 24 hours of life
|
|
Neonates' number of mobile and immobile bouts in 24 hours
기간: Within the first 24 hours of life
|
Within the first 24 hours of life
|
|
Total activity score
기간: Within the first 24 hours of life
|
Within the first 24 hours of life
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Neonates' total sleep time in 24 hours, night-time sleep in 24 hours and day-time sleep in 24 hours
기간: Within the first 24 hours of life
|
Within the first 24 hours of life
|
|
Neonates' total number of sleep bouts
기간: Within the first 24 hours of life
|
Within the first 24 hours of life
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Naomi Kronitz, MD, FRCPC, Department of Anesthesia BC Women's Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .